AFC
UTHR icon

Ares Financial Consulting’s United Therapeutics UTHR Stock Holding History

Ares Financial Consulting’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.79K Buy
7
+4
+133% +$2.25K ﹤0.01% 780
2026
Q1 		$1.71K Hold
3
– – ﹤0.01% 871
2025
Q4 		$1.46K Buy
+3
New +$1.4K ﹤0.01% 713

Other funds holding UTHR

AssetMark Inc
AssetMark Inc Concord, California $58.2B AUM 22.78% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Ares Financial Consulting's UTHR Position: Q2 2026 in Review

Ares Financial Consulting increased its United Therapeutics (UTHR) stake by 133% in Q2 2026, buying an estimated $2.25K and bringing the position to 7 shares worth $3.79K. The position accounts for ﹤0.01% of the portfolio, ranked #780.

Ares Financial Consulting first reported a position in UTHR in Q4 2025 and has held it in 3 quarters since. 379 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Ares Financial Consulting held 7 shares of United Therapeutics worth $3.79K as of Q2 2026.
  • Ares Financial Consulting bought 4 United Therapeutics shares in Q2 2026, an estimated $2.25K.
  • United Therapeutics made up ﹤0.01% of Ares Financial Consulting's portfolio in Q2 2026, its #780 holding.
  • Ares Financial Consulting first reported a position in United Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 379 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Ares Financial Consulting's 13F filing for Q2 2026, filed 9 Jul 2026.